Company profile
Integrated BioPharma, Inc.
OTC: INBP · Healthcare · Medical - Pharmaceuticals
PublicHQ Hillside, NJCIK 0001016504Reports USD
#421 of 1,422 Healthcare companies by revenue53rd-percentile growth
EA Score
67BFH 72DQ 65GM 58SS 67
v0.1 · 65/100 weight · provisional
↑ listing tenure, return on assets · ↓ Piotroski F, 3-yr revenue growth
Methodology →Revenue TTM
$48.3M
Rev growth YoY (TTM)
-8.8%
Net income (FY)
$808.0k
Employees
153
as of 2026-08-23
Market cap
$5.6M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$54.4M$54.4M2025
Net income$808.0k$808.0k2025
Operating income$2.0M$2.0M2025
Total assets$24.9M$24.9M2025
Liabilities$4.6M$4.6M2025
Equity$20.3M$20.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2018
By product
Contract Manufacturing96%
Other Nutraceutical Business3%
Branded Proprietary Products1%
By geography
Europe and Canada100%
The read
What is Integrated BioPharma, Inc.’s revenue?
Integrated BioPharma, Inc. booked $54.4M in FY2025 revenue, growing 8.0% year over year — about the middle of the pack among Healthcare companies we track, at a 1.5% net margin.
Peers · Healthcare
908 Devices Inc.60CNektar Therapeutics50DThe Joint Corp.75B+Agios Pharmaceuticals, Inc.70BQ32 Bio Inc.72BInvivyd, Inc.41DKey facts
CEORiva Sheppard
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersHillside, NJ
ExchangeOTC: INBP
Employees153
IPO date1996-10-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.